NEW ORLEANS – Available medications to treat CML are giving rise to new questions. For instance, why do some patients respond to some medications better than others? How can side effects best be managed? And how can treatment be stopped safely?
In an exclusive interview at the American Society of Hematology's annual meeting, Dr. Richard E. Clark of Royal Liverpool University Hospital, Liverpool, United Kingdom, provides an overview of the field and its future.